U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT06927999) titled 'An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria' on April 04.
Brief Summary: This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Urticaria Chronic
Intervention:
DRUG: Placebo
Placebo solution nasal spray containing no active drug
DRUG: 0.5 mg epinephrine
0.5 mg epinephrine...